Article

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta

2020-05-05

Abstract excerpt

<h4>Background: </h4> Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide association study on ADA and predict the occurrence of antibodies in multiple sclerosis patients treated with d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebfe1595-f346-55f6-97cb-fd9e432ee25c
DOI: 10.1101/2020.05.01.20086033

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaDOI 10.1101/2020.05.01.20086033Read

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.Semantic proximity Read

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.Semantic proximity Read

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.Semantic proximity Read

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Semantic proximity Read

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.Semantic proximity Read

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read

Pharmacogenetics of multiple sclerosisSemantic proximity Read

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.Semantic proximity Read

Immunopharmacological consequences of immune responses to therapeutic interferon betaSemantic proximity Read

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read